Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.
Schneider LS, Bennett DA, Farlow MR, Peskind ER, Raskind MA, Sano M, Stern Y, Haneline S, Welsh-Bohmer KA, O'Neil J, Walter R, Maresca S, Culp M, Alexander R, Saunders AM, Burns DK, Chiang C.
Schneider LS, et al. Among authors: maresca s.
J Prev Alzheimers Dis. 2022;9(4):625-634. doi: 10.14283/jpad.2022.72.
J Prev Alzheimers Dis. 2022.
PMID: 36281666
Clinical Trial.